And metabolic impact analysis indicated that treatment with L-carnitine combined with trimetazidine can perturb the metabolism of amino acids, branched-chain amino acids, carbohydrates, and TCA intermediates (Figure 7B)
Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis
It is also seen in human cells, which helps to produce proteins in the system
Survodutide, as a dual GLP-1/glucagon receptor agonist, further supports the plausibility of glucagon receptor activation as a useful therapeutic component when paired with GLP-1 signaling
Early clinical research has shown significant fat-loss outcomes under medical supervision, positioning it as one of the most advanced metabolic therapies in development